Wonganan Piyanuch, Jonsson-Schmunk Kristina, Callahan Shellie M, Choi Jin Huk, Croyle Maria A
Division of Pharmaceutics, College of Pharmacy (P.W., K. J.-S., S. M. C., J.-H. C. and M. A. C.) and the Institute of Cellular and Molecular Biology (M. A. C.), The University of Texas at Austin, Austin, Texas.
Division of Pharmaceutics, College of Pharmacy (P.W., K. J.-S., S. M. C., J.-H. C. and M. A. C.) and the Institute of Cellular and Molecular Biology (M. A. C.), The University of Texas at Austin, Austin, Texas
Drug Metab Dispos. 2014 Jul;42(7):1191-201. doi: 10.1124/dmd.113.056663. Epub 2014 Apr 24.
HC-04 cells were evaluated as an in vitro model for mechanistic study of changes in the function of hepatic CYP3A during virus infection. Similar to in vivo observations, infection with a first generation recombinant adenovirus significantly inhibited CYP3A4 catalytic activity in an isoform-specific manner. Virus (MOI 100) significantly reduced expression of the retinoid X receptor (RXR) by 30% 96 hours after infection. Cytoplasmic concentrations of the pregnane X receptor (PXR) were reduced by 50%, whereas the amount of the constitutive androstane receptor (CAR) in the nuclear fraction doubled with respect to uninfected controls. Hepatocyte nuclear factor 4α (HNF-4α) and peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) were also reduced by ∼70% during infection. Virus suppressed CYP3A4 activity in the presence of the PXR agonist rifampicin and did not affect CYP3A4 activity in the presence of the CAR agonist CITCO [6-(4-chlorophenyl) imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime], suggesting that virus-induced modification of PXR may be responsible for observed changes in hepatic CYP3A4. The HC-04 cell line is easy to maintain, and CYP3A4 in these cells was responsive to known inducers and suppressors. Dexamethasone (200 μM) and phenobarbital (500 μM) increased activity by 230 and 124%, whereas ketoconazole (10 μM) and lipopolysaccharide (LPS) (10 μg/ml) reduced activity by 90 and 92%, respectively. This suggests that HC-04 cells can be a valuable tool for mechanistic study of drug metabolism during infection and for routine toxicological screening of novel compounds prior to use in the clinic.
HC-04细胞被评估为一种体外模型,用于病毒感染期间肝脏CYP3A功能变化的机制研究。与体内观察结果相似,第一代重组腺病毒感染以异构体特异性方式显著抑制CYP3A4催化活性。感染96小时后,病毒(感染复数为100)使视黄酸X受体(RXR)的表达显著降低30%。孕烷X受体(PXR)的细胞质浓度降低50%,而与未感染对照相比,核部分组成型雄烷受体(CAR)的量增加一倍。感染期间,肝细胞核因子4α(HNF-4α)和过氧化物酶体增殖物激活受体γ共激活因子1α(PGC-1α)也降低了约70%。在存在PXR激动剂利福平的情况下,病毒抑制CYP3A4活性,而在存在CAR激动剂CITCO [6-(4-氯苯基)咪唑[2,1-b][1,3]噻唑-5-甲醛-O-(3,4-二氯苄基)肟]的情况下,病毒不影响CYP3A4活性,这表明病毒诱导的PXR修饰可能是肝脏CYP3A4观察到的变化的原因。HC-04细胞系易于维持,这些细胞中的CYP3A4对已知的诱导剂和抑制剂有反应。地塞米松(200μM)和苯巴比妥(500μM)使活性分别增加230%和124%,而酮康唑(10μM)和脂多糖(LPS)(10μg/ml)分别使活性降低90%和92%。这表明HC-04细胞可以成为感染期间药物代谢机制研究以及新型化合物在临床应用前进行常规毒理学筛选的有价值工具。